133 related articles for article (PubMed ID: 34593171)
1. Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance.
Pauly MV; Comanor WS; Frech HE; Martinez JR
Value Health; 2021 Oct; 24(10):1476-1483. PubMed ID: 34593171
[TBL] [Abstract][Full Text] [Related]
2. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis in markets with high fixed costs.
Cutler DM; Ericson KM
Pharmacoeconomics; 2010; 28(10):867-75. PubMed ID: 20831294
[TBL] [Abstract][Full Text] [Related]
4. Healthcare reform in the United States and China: pharmaceutical market implications.
Daemmrich A; Mohanty A
J Pharm Policy Pract; 2014; 7(1):9. PubMed ID: 25097759
[TBL] [Abstract][Full Text] [Related]
5. Switching costs in competitive health insurance markets: The role of insurers' pricing strategies.
Lamiraud K; Stadelmann P
Health Econ; 2020 Sep; 29(9):992-1012. PubMed ID: 32542729
[TBL] [Abstract][Full Text] [Related]
6. Do pharmaceutical prices rise anticipating branded competition?
Ellyson AM; Basu A
Health Econ; 2021 May; 30(5):1070-1081. PubMed ID: 33684255
[TBL] [Abstract][Full Text] [Related]
7. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
8. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
[TBL] [Abstract][Full Text] [Related]
9. Pricing of drugs with heterogeneous health insurance coverage.
Ferrara I; Missios P
J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
[TBL] [Abstract][Full Text] [Related]
10. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
12. Insurance access and demand response: Pricing and welfare implications.
Besanko D; Dranove D; Garthwaite C
J Health Econ; 2020 Sep; 73():102329. PubMed ID: 32603854
[TBL] [Abstract][Full Text] [Related]
13. Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
Herr A; Suppliet M
J Health Econ; 2017 Dec; 56():19-29. PubMed ID: 28964941
[TBL] [Abstract][Full Text] [Related]
14. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
15. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
Pauly MV
Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209
[TBL] [Abstract][Full Text] [Related]
16. Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.
Douven RC; Schut FT
J Health Econ; 2011 Mar; 30(2):439-49. PubMed ID: 21295365
[TBL] [Abstract][Full Text] [Related]
17. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
18. Reference pricing and firms' pricing strategies.
Miraldo M
J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
[TBL] [Abstract][Full Text] [Related]
19. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
20. Toward a Hedonic Value Framework in Health Care.
Basu A; Sullivan SD
Value Health; 2017 Feb; 20(2):261-265. PubMed ID: 28237206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
